These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 18803811)

  • 21. High prevalence of germline CDKN2A mutations in Slovenian cutaneous malignant melanoma families.
    Hocevar M; Avbelj M; Perić B; Zgajnar J; Besić N; Battelino T
    Croat Med J; 2006 Dec; 47(6):851-4. PubMed ID: 17167857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
    Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F
    J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study.
    Fargnoli MC; Altobelli E; Keller G; Chimenti S; Höfler H; Peris K
    Melanoma Res; 2006 Apr; 16(2):175-82. PubMed ID: 16567973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.
    Demenais F; Mohamdi H; Chaudru V; Goldstein AM; Newton Bishop JA; Bishop DT; Kanetsky PA; Hayward NK; Gillanders E; Elder DE; Avril MF; Azizi E; van Belle P; Bergman W; Bianchi-Scarrà G; Bressac-de Paillerets B; Calista D; Carrera C; Hansson J; Harland M; Hogg D; Höiom V; Holland EA; Ingvar C; Landi MT; Lang JM; Mackie RM; Mann GJ; Ming ME; Njauw CJ; Olsson H; Palmer J; Pastorino L; Puig S; Randerson-Moor J; Stark M; Tsao H; Tucker MA; van der Velden P; Yang XR; Gruis N;
    J Natl Cancer Inst; 2010 Oct; 102(20):1568-83. PubMed ID: 20876876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDKN2A mutations in multiple primary melanomas.
    Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ
    N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MC1R variation and melanoma risk in relation to host/clinical and environmental factors in CDKN2A positive and negative melanoma patients.
    Ghiorzo P; Bonelli L; Pastorino L; Bruno W; Barile M; Andreotti V; Nasti S; Battistuzzi L; Grosso M; Bianchi-Scarrà G; Queirolo P
    Exp Dermatol; 2012 Sep; 21(9):718-20. PubMed ID: 22804906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDKN2A and MC1R analysis in amelanotic and pigmented melanoma.
    Ghiorzo P; Pastorino L; Pizzichetta MA; Bono R; Queirolo P; Talamini R; Annessi G; Bruno W; Nasti S; Gargiulo S; Battistuzzi L; Sini MC; Palmieri G; Scarrà GB;
    Melanoma Res; 2009 Jun; 19(3):142-5. PubMed ID: 19339902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma.
    Pho L; Grossman D; Leachman SA
    Curr Opin Oncol; 2006 Mar; 18(2):173-9. PubMed ID: 16462187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.
    Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S
    JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients.
    Council ML; Gardner JM; Helms C; Liu Y; Cornelius LA; Bowcock AM
    Exp Dermatol; 2009 May; 18(5):485-7. PubMed ID: 19320745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
    Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
    Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
    Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
    Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
    Holland EA; Schmid H; Kefford RF; Mann GJ
    Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotypic and histologic characteristics of cutaneous melanoma in patients with melanocortin-1 receptor polymorphisms.
    Avilés JA; Lázaro P; Fernández LP; Benítez J; Ibarrola-Villava M; Ribas G
    Actas Dermosifiliogr; 2012 Jan; 103(1):44-50. PubMed ID: 22464597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters.
    Karagianni F; Njauw CN; Kypreou KP; Stergiopoulou A; Plaka M; Polydorou D; Chasapi V; Pappas L; Stratigos IA; Champsas G; Panagiotou P; Gogas H; Evangelou E; Tsao H; Stratigos AJ; Stefanaki I
    Acta Derm Venereol; 2018 Oct; 98(9):862-866. PubMed ID: 29774366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
    Borroni RG; Manganoni AM; Grassi S; Grasso M; Diegoli M; Giorgianni C; Favalli V; Pavoni L; Cespa M; Arbustini E
    Melanoma Res; 2017 Apr; 27(2):97-103. PubMed ID: 28060055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation.
    van der Rhee JI; Boonk SE; Putter H; Cannegieter SC; Flinterman LE; Hes FJ; de Snoo FA; Mooi WJ; Gruis NA; Vasen HF; Kukutsch NA; Bergman W
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1771-7. PubMed ID: 23897584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
    Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
    Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genotype analysis in Hungarian patients with multiple primary melanoma.
    Hatvani Z; Brodszky V; Mazán M; Pintér D; Hársing J; Tóth V; Somlai B; Kárpáti S
    Exp Dermatol; 2014 May; 23(5):361-4. PubMed ID: 24660985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of Potential Melanoma Predisposition Genes in High-Risk Brazilian Patients.
    Soares de Sá BC; Moredo LF; Torrezan GT; Fidalgo F; de Araújo ÉSS; Formiga MN; Duprat JP; Carraro DM
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.